Lars Ek

2.3k total citations
31 papers, 1.4k citations indexed

About

Lars Ek is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Lars Ek has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Lars Ek's work include Lung Cancer Diagnosis and Treatment (6 papers), Receptor Mechanisms and Signaling (5 papers) and Lung Cancer Research Studies (4 papers). Lars Ek is often cited by papers focused on Lung Cancer Diagnosis and Treatment (6 papers), Receptor Mechanisms and Signaling (5 papers) and Lung Cancer Research Studies (4 papers). Lars Ek collaborates with scholars based in Sweden, Netherlands and Germany. Lars Ek's co-authors include Bengt Åblad, Steven Nordin, Annika Brämerson, Mats Bende, Leif Johansson, Enar Carlsson, Carl‐Gunnar Regårdh, Joachim H. Ficker, Dirk‐Jan Slebos and Daniela Gompelmann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and CHEST Journal.

In The Last Decade

Lars Ek

30 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Ek Sweden 16 423 334 308 286 249 31 1.4k
Christoph Eisner Germany 16 107 0.3× 157 0.5× 48 0.2× 146 0.5× 392 1.6× 31 1.4k
Mamoru Takahashi Japan 21 28 0.1× 244 0.7× 125 0.4× 44 0.2× 371 1.5× 80 1.6k
Sandeep S Hothi United Kingdom 12 342 0.8× 73 0.2× 83 0.3× 44 0.2× 371 1.5× 43 1.0k
Shigeru Furuta Japan 15 69 0.2× 89 0.3× 53 0.2× 78 0.3× 113 0.5× 71 771
Ann Meulemans Belgium 24 53 0.1× 72 0.2× 57 0.2× 113 0.4× 399 1.6× 81 1.7k
Yuanlin Ding China 20 54 0.1× 86 0.3× 29 0.1× 103 0.4× 757 3.0× 52 1.5k
Andreas Thalheimer Germany 23 23 0.1× 378 1.1× 34 0.1× 167 0.6× 315 1.3× 64 2.0k
Akiko Yamamoto Japan 17 32 0.1× 52 0.2× 64 0.2× 117 0.4× 169 0.7× 60 1.1k
Serge Duckett United States 21 20 0.0× 103 0.3× 83 0.3× 176 0.6× 225 0.9× 76 1.2k
Lothar Eckel Germany 20 15 0.0× 97 0.3× 70 0.2× 102 0.4× 298 1.2× 48 1.4k

Countries citing papers authored by Lars Ek

Since Specialization
Citations

This map shows the geographic impact of Lars Ek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Ek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Ek more than expected).

Fields of papers citing papers by Lars Ek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Ek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Ek. The network helps show where Lars Ek may publish in the future.

Co-authorship network of co-authors of Lars Ek

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Ek. A scholar is included among the top collaborators of Lars Ek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Ek. Lars Ek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brunnström, Hans, et al.. (2022). Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLC—A retrospective single-center experience. PLoS ONE. 17(2). e0263342–e0263342. 4 indexed citations
2.
Lindquist, Kajsa Ericson, Anna Karlsson, Per Levéen, et al.. (2017). Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget. 8(21). 34796–34810. 41 indexed citations
3.
Gulyás, Miklós, Johanna Sofia Margareta Mattsson, Andrea Lindgren, et al.. (2017). COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer. Acta Oncologica. 57(2). 244–250. 21 indexed citations
4.
Sörenson, Sverre, Helena Fohlin, Andrea Lindgren, et al.. (2012). Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. European Journal of Cancer. 49(1). 115–120. 13 indexed citations
5.
Herth, Felix, Ralf Eberhardt, Daniela Gompelmann, et al.. (2012). Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment. European Respiratory Journal. 41(2). 302–308. 174 indexed citations
6.
Gompelmann, Daniela, Ralf Eberhardt, Dirk‐Jan Slebos, et al.. (2012). Pneumothorax as a predictor of beneficial outcome following endoscopic lung volume reduction. 40. 4728. 2 indexed citations
7.
Koch, Andrea, Bengt Bergman, Erik Holmberg, et al.. (2011). Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. European Journal of Cancer. 47(10). 1546–1555. 48 indexed citations
8.
Ek, Lars, et al.. (2011). Diagnostic yield and efficacy of endobronchial ultrasound‐guided transbronchial needle aspiration in mediastinal lymphadenopathy. The Clinical Respiratory Journal. 6(2). 88–95. 17 indexed citations
9.
Gompelmann, Daniela, Ralf Eberhardt, Dirk‐Jan Slebos, et al.. (2011). Comparison between Chartis® pulmonary assessment system detection of collateral ventilation vs. corelab CT fissure analysis in predicting atelectasis in emphysema patients treated with endobronchial valves. European Respiratory Journal. 38(Suppl 55). p3536–p3536. 5 indexed citations
10.
Brämerson, Annika, Leif Johansson, Lars Ek, Steven Nordin, & Mats Bende. (2004). Prevalence of Olfactory Dysfunction: The Skövde Population‐Based Study. The Laryngoscope. 114(4). 733–737. 434 indexed citations
11.
Helsing, Martin, Lars Thaning, Christer Sederholm, et al.. (1999). Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Lung Cancer. 24(2). 107–113. 9 indexed citations
12.
Andersson, Morgan, N. Lindqvist, C. Svensson, Lars Ek, & Ulf Pipkorn. (1993). Dry powder inhalation of budesonide in allergic rhinitis. Clinical Otolaryngology. 18(1). 30–33. 17 indexed citations
13.
Björkman, Jan‐Arne, Lars Ek, David Gustafsson, Bengt Ljung, & Margareta Nordlander. (1991). Acute Haemodynamic Effects of Felodipine, Verapamil and Hydralazine in the Anaesthetized Dog. Pharmacology & Toxicology. 68(4). 310–315. 6 indexed citations
14.
Schröder, U, et al.. (1988). Prediction of behavior management problems in children. European Journal Of Oral Sciences. 96(5). 457–465. 40 indexed citations
15.
Åblad, Bengt, Tommy Abrahamsson, Jan‐Arne Björkman, et al.. (1987). Cardiac Antiischemic Effect of Metoprolol. Journal of Cardiovascular Pharmacology. 10. S117–125. 11 indexed citations
16.
Åblad, Bengt, Tommy Abrahamsson, Jan‐Arne Björkman, et al.. (1987). Cardiac Antiischemic Effect of Metoprolol. Journal of Cardiovascular Pharmacology. 10. S117–125. 2 indexed citations
17.
18.
Regårdh, Carl‐Gunnar, Lars Ek, & Kurt Hoffmann. (1979). Plasma levels and β-blocking effect of α-hydroxymetoprolol—Metabolite of metoprolol—in the dog. Journal of Pharmacokinetics and Biopharmaceutics. 7(5). 471–479. 30 indexed citations
19.
Åblad, Bengt, K. O. Borg, Enar Carlsson, et al.. (1975). A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacologica et Toxicologica. 36(s5). 7–23. 126 indexed citations
20.
Åblad, Bengt, Enar Carlsson, & Lars Ek. (1973). Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. Life Sciences. 12(3). 107–119. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christoph Eisner Breakdown of academic impact, for papers by Mamoru Takahashi Breakdown of academic impact, for papers by Sandeep S Hothi Breakdown of academic impact, for papers by Shigeru Furuta Breakdown of academic impact, for papers by Ann Meulemans Breakdown of academic impact, for papers by Yuanlin Ding Breakdown of academic impact, for papers by Andreas Thalheimer Breakdown of academic impact, for papers by Akiko Yamamoto Breakdown of academic impact, for papers by Serge Duckett Breakdown of academic impact, for papers by Lothar Eckel
Rankless by CCL
2026